What is Semax?
Semax is a seven-amino-acid peptide investigated in neurobiological research. The selected study examines responses to experimental brain ischemia.
Video overview · 2:47
Semax vs Selank: Do These Russian "Brain Peptides" Actually Work? (The Evidence)
What each peptide is, the rat brain studies behind the memory claim, the small Russian stroke and anxiety studies, why no placebo-controlled trial has tested memory or focus in healthy people, and their FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Semax and Selank are two short peptides developed in Russia and sold online as brain boosters: Semax for focus, Selank for calm. Neither is FDA approved, and the evidence behind them is thinner than the marketing suggests. Here is what is actually known.
Semax is seven amino acids long, built from a fragment of the stress hormone ACTH that researchers once linked to learning. Selank was developed in Russia and studied mainly for anxiety. Both are reported to be used as medicines in Russia, but little of their research reached international journals, and online they are sold as powders and nasal sprays outside any quality control.
Most of the memory story comes from rats. A single nasal application of Semax raised BDNF, a protein that supports brain-cell growth, by up to one point four times in the rat brain's memory center, and treated rats learned an avoidance task better. Whether any of that means sharper focus in healthy people has not been shown.
The human studies are small, mostly Russian, and not clearly blinded. Semax was added to standard care in thirty stroke patients, compared with eighty others, and the authors reported faster recovery. Selank was compared with two anxiety drugs, in sixty and sixty-two patients, and reported similar anxiety improvement. None had a placebo group.
What about healthy people? For Semax, we found no published placebo-controlled trial that measured memory or focus. Two Russian studies in healthy volunteers looked only at brain scans. And when the hormone fragment Semax was built from was properly tested in sixty healthy people, it did not improve working memory.
Neither is FDA approved. The FDA says it lacks important safety information for both and flags possible immune reactions from impurities, and in 2026, FDA staff advised against allowing Semax in pharmacy compounding. Because they are reported to be registered in Russia, their status under anti-doping rules is unclear.
Does Semax boost memory in healthy people? Unproven: no placebo-controlled trial has measured it. Does Selank treat anxiety? The evidence is limited to two small studies without a placebo group. And is the Semax and Selank combination tested? No study has tested them together.
The bottom line: Semax and Selank rest on rat studies and small Russian reports. The memory claim for Semax is unproven in healthy people, Selank's anxiety evidence lacks a placebo group, and neither is FDA approved. For the full comparison and every source, see PepsRadar dot com.
Biological role or research focus
Neurobiological and cerebral-ischemia research.
Animal brain findings do not demonstrate improved focus or mood in otherwise healthy people.
- Class / identity
- Experimental neuroactive heptapeptide
- Main research area
- Brain-ischemia biology
- Evidence featured
- Rat brain experiment
- Source check
- October 4, 2026
Quick answers
- Is Semax FDA approved?
- No. No FDA-approved drug contains Semax. Source ↗
- Is Semax safe?
- Not FDA-approved. Human evidence is small Russian clinical reports, and FDA says it cannot tell whether Semax would cause harm, so its risks are uncertain. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Semax banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Semax?
- Yes. Our records list 4 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Ischemia transcriptome study (2014) | Rat brain experiment | Rats after experimentally induced focal cerebral ischemia. |
| Semax · early clinical stroke report (1997) | Human comparative study | 30 treated patients with acute hemispheric ischemic stroke and 80 controls described as having comparable lesion location and severity. |
Claim check
Unproven Does Semax improve memory and focus in healthy people?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Rat brain experiment · 2014
Ischemia transcriptome study
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.
- Population / model
- Rats after experimentally induced focal cerebral ischemia.
- Study design
- Brain-cortex gene expression measured three and 24 hours after arterial occlusion.
- Main finding
- Semax altered expression of immune- and vascular-system genes, including chemokine and immunoglobulin-related pathways.
- Limits & context
- Gene-expression changes do not demonstrate improved everyday attention, memory, or mood in healthy humans. The experiment models a brain injury and does not establish a clinical benefit-risk balance.
Human comparative study · 1997
Semax · early clinical stroke report
What clinical evidence accompanies the animal mechanism research?
- Population / model
- 30 treated patients with acute hemispheric ischemic stroke and 80 controls described as having comparable lesion location and severity.
- Study design
- Clinical scales, EEG, and somatosensory evoked potentials alongside conventional intensive therapy. Randomization and blinding are not stated in the abstract.
- Main finding
- The authors reported faster regression of neurological deficits, especially motor impairment, with added Semax; numerical treatment effects and confidence intervals are not provided.
- How to read it
- A comparative clinical report is a different evidence level from a well-described blinded randomized trial.
- Limits & context
- Unequal groups, unclear allocation, and limited reporting leave substantial uncertainty. The Russian-language methods require review. Acute stroke findings cannot establish memory enhancement in healthy people or modern clinical practice recommendations.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Semax as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
Not FDA-approved. Human evidence is small Russian clinical reports, and FDA says it cannot tell whether Semax would cause harm, so its risks are uncertain.
Human data are mainly small Russian clinical reports, such as a stroke study of 30 treated patients without clear randomization. FDA says it has no or limited safety information for proposed uses. Long-term neurological safety is unknown.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · Semax in acute hemispheric ischemic stroke (2001) ↗ · Semax and gene expression in rat brain ischemia (2014) ↗
Safety evidence & remaining uncertainty
FDA describes limited route-specific safety evidence. Gene-expression experiments cannot establish tolerability, drug interactions, or long-term neurological safety in people.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Semax (heptapeptide)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented semax (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 24, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering Semax (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; Semax is reported to be registered as a medicine in Russia (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source
FDA actions
- HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Semax is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add Semax to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
- FDA presented semax (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Semax among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
- FDA warning letter to a clinic-based compounder (Guyer Institute) stating Semax had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
This page presents a rat-brain experiment. It does not establish an everyday focus, mood, or memory indication in healthy people.
Some sellers also offer "Adamax," described as an adamantane-modified Semax analog. No published studies of Adamax itself were found in PubMed when checked on October 15, 2026, so its claimed effects are borrowed from Semax research, and seller descriptions disagree on its structure: some describe an added adamantane group, while others describe an extended, acetylated Semax sequence without one.
Source: PubMed search: Adamax and Semax · no records found · checked October 15, 2026 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Researchers measured changes in immune- and vascular-related gene expression after injury. These molecular responses suggest pathways for investigation, not a verified cognitive-enhancement effect.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Animal brain findings do not demonstrate improved focus or mood in otherwise healthy people.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Was the experiment performed in healthy people seeking focus?
No. It used rats after induced cerebral ischemia.
Does a gene-expression change show better brain function?
Not by itself. Functional recovery and meaningful clinical outcomes require separate measurements.
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Rat cerebral-ischemia model · PMID 24661604 ↗
- PubMed search: Adamax and Semax · no records found · checked October 15, 2026 ↗
- Semax · early clinical stroke report · 1997 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Which peptides can pharmacies compound now? The 2026 HHS peptide policy explained
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Read the guide →
